[1] Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology, 2019,156(6):1582-1599,e1581. [2] Ogren M, Bergqvist D, Bjorck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol, 2006,12(13):2115-2119. [3] Ageno W, Dentali F, Pomero F, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari syndrome. Thromb Haemost, 2017,117(4):794-80. [4] Senzolo M, Garcia-Tsao G, Garcia-Pagan JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol, 2021,75(2):442-453. [5] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974. [6] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology, 2021,73(1):366-413. [7] Hepatobiliary Disease Study Group CSoGCMA. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis, 2021,22(4):176-186. [8] Seedial SM, Mouli SK, Desai KR. Acute portal vein thrombosis: current trends in medical and endovascular management. Semin Intervent Radiol, 2018,35(3):198-202. [9] Rajesh S, George T, Philips CA, et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: an exhaustive critical update. World J Gastroenterol, 2020,26(37):5561-5596. [10] Wan YM, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost, 2018,24(3):462-470. [11] Wang Z, Jiang MS, Zhang HL, et al. Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? a randomized controlled trial. Radiology, 2016,279(3):943-951. [12] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology, 2017,153(2):480-487,e481. [13] Irarrazaval S, Allard C, Campodonico J, et al. Oxidative stress in hypobaric hypoxia. High Alt Med Biol,2017,18(2):128-134. [14] Kim M, Alapan Y, Adhikari A, et al. Hypoxia-enhanced adhesion of red blood cells in microscale flow. Microcirculation, 2017,24(5):10. [15] Rocke AS, Paterson GG, Barber MT, et al. Thromboelastometry and platelet function during acclimatization to high altitude. Thromb Haemost,2018,118(1):63-71. [16] Mahmoodi BK, Brouwer JL, Veeger NJ, et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation, 2008,118(16):1659-1667. [17] Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol,2010,85(12):947-950. [18] Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology, 2010,51(1):210-218. [19] Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clin Exp Gastroenterol, 2018,11:373-380. [20] Basili S, Carnevale R, Nocella C, et al. Serum albumin is inversely associated with portal vein thrombosis in cirrhosis. Hepatol Commun,2019,3(4):504-512. |